Synergistic compositions useful as anti-tumor agents
AssigneeOctamer, Inc.
InventorsErnest Kun, Jerome Mendeleyev, Eva Kirsten
Life of this patent
Estimating the term…
Abstract
The subject invention provides for novel synergistic compositions useful for inactivating viruses or inducing apoptosis in tumor cells and for treating cancer or retroviral infections. Generally, the compositions comprise one or a plurality of ligands that oxidatively attack a zinc finger of pADPRT in combination with one or a plurality of agents selected from the group consisting of: agents that decrease cellular levels of glutathione and ligands that non-covalently bind to the nicotinamide site of pADPRT but do not effect zinc ejection from a zinc finger of pADPRT.
Claims6
A synergistic composition comprising one or a plurality of pADPRT CCHC-oxidizing ligands in combination with one or a plurality of non-covalent pADPRT-inhibitory ligands wherein the pADPRT CCHC-oxidizing ligands are selected from the group consisting of:
- a compound having the formula:
- ##STR15## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are, independent of one another, selected from the group consisting of hydrogen, hydroxy, nitroso, nitro, iodo, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, (C.sub.3 -C.sub.7) cycloalkyl, and phenyl and pharmaceutically acceptable salts thereof, wherein at least three of the six R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 substituents are hydrogen and wherein at least one of the six R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 substituents is nitroso or nitro;
- a compound having the formula:
- ##STR16## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are, independent of one another, selected from the group consisting of hydrogen, hydroxy, nitroso, nitro, iodo, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, (C.sub.3 -C.sub.7) cycloalkyl, and phenyl and pharmaceutically acceptable salts thereof, wherein at least two of the five R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 substituents are hydrogen and wherein at least one of the six R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 substituents is nitroso or nitro;
- and a compound having the formula:
- ##STR17## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are, independent of one another, selected from the group consisting of hydrogen, hydroxy, nitroso, nitro, iodo, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, (C.sub.3 -C.sub.7) cycloalkyl, and phenyl and pharmaceutically acceptable salts thereof, wherein at least two of the five R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 substituents are hydrogen and wherein at least one of the five R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 substituents is nitroso or nitro;
- and wherein the non-covalent pADPRT-inhibitory ligands are selected from the group consisting of:
- a compound having the formula ##STR18## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are, independent of one another, selected from the group consisting of hydrogen, hydroxy, amino, iodo, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, (C.sub.3 -C.sub.7) cycloalkyl, and phenyl and pharmaceutically acceptable salts thereof, wherein at least three of the six R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 substituents are hydrogen;
- and
- a compound having the formula:
- ##STR19## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are, independent of one another, selected from the group consisting of hydrogen, hydroxy, amino, iodo, alkyl, (C.sub.1 -C.sub.6) alkoxy, (C.sub.3 -C.sub.7) cycloalkyl, and phenyl and pharmaceutically acceptable salts thereof, wherein at least three of the six R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 substituents are hydrogen.
Dependencies are inferred from the claim text.